In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...
Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...
HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...
A groundbreaking study from Tata Memorial Hospital shows that using ultra-low doses of nivolumab, an immunotherapy drug, can effectively treat cancer while drastically reducing costs by 90%. This ...
Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for papillary ...
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms ...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has been successfully dosed in a Phase ? clinical study ...
Earnings call Coherus Oncology doubled LOQTORZI sales to $40.8M in 2025 (113% YoY growth), achieved a 90%+ debt reduction, and completed its transformation into a focused oncology innovator.
A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results